Diplomat Pharmacy (NYSE:DPLO) released its earnings results on Tuesday. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.21), Fidelity Earnings reports. Diplomat Pharmacy had a return on equity of 7.86% and a net margin of 0.06%. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.42 billion. During the same period last year, the business earned $0.01 earnings per share. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. Diplomat Pharmacy updated its FY18 guidance to $(0.10)-$0.03 EPS.
NYSE DPLO traded down $5.54 during trading on Wednesday, reaching $14.80. 7,207,508 shares of the company traded hands, compared to its average volume of 987,505. The company has a current ratio of 0.91, a quick ratio of 0.63 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of 17.62 and a beta of 0.95. Diplomat Pharmacy has a 1-year low of $13.31 and a 1-year high of $28.74.
DPLO has been the topic of a number of recent research reports. ValuEngine downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th. Zacks Investment Research raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, Robert W. Baird downgraded Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $22.00 to $10.00 in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $26.10.
In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 57,500 shares of Diplomat Pharmacy stock in a transaction that occurred on Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total transaction of $1,104,575.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Philip R. Hagerman sold 209,367 shares of Diplomat Pharmacy stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $19.07, for a total transaction of $3,992,628.69. The disclosure for this sale can be found here. 24.70% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Diplomat Pharmacy (DPLO) Issues Earnings Results, Misses Expectations By $0.21 EPS” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/11/07/diplomat-pharmacy-dplo-issues-earnings-results-misses-expectations-by-0-21-eps.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Further Reading: Why investors pay attention to retained earnings
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.